Genmab Increases Share Capital Following Employee Warrant Exercise
Company Announcement
Genmab A/S (Nasdaq: GMAB) recently reported a significant development in its capital structure with the increase of its share capital due to the exercise of employee warrants.
This increase involves the issuance of 4,563 new shares, which is a strategic move on part of the company to align employee incentives and fortify its financial foundation. Importantly, these shares have been issued without preemption rights for current shareholders, which allows the company to streamline this process.
Details of the Capital Increase
The shares have been subscribed for cash at various prices. Specifically, 2,580 shares were issued at DKK 1,025.00, another 1,874 shares at DKK 1,050.00, and 109 shares at a higher price of DKK 1,161.00. This capital raise is expected to generate approximately DKK 4.7 million, enhancing the company's resources.
Following the exercise, the share capital of Genmab A/S stands at DKK 64,158,817, which is divided into 64,158,817 ordinary shares, each with a nominal value of DKK 1. This structure ensures that Genmab continues to uphold its commitment to its growth and innovation strategies in the biotechnology landscape.
The Nature of the New Shares
The new shares are considered ordinary shares, which do not entail any special rights and are fully transferable. Shareholders can expect these new shares to participate in dividends and the overall rights associated with the company, beginning from the moment of subscription. Moreover, these shares will become part of the listings on Nasdaq Copenhagen once officially registered.
There is a strong emphasis on the quick finalization of this capital increase, reflecting Genmab’s dedication to remaining proactive in financial maneuvers that support its innovative pipeline.
The Vision of Genmab
About Genmab
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab is devoted to improving the lives of patients through cutting-edge antibody therapeutics. With over 25 years of dedicated effort, Genmab has developed exceptional antibody technology platforms. These platforms support a diverse pipeline filled with products like bispecific T-cell engagers, antibody-drug conjugates, and novel immune checkpoint inhibitors.
Genmab aims to revolutionize the treatment landscape for cancer and other severe illnesses with groundbreaking antibody medicines by 2030, demonstrating its commitment to pushing the boundaries of what is possible in biotechnology.
Company's Commitment and Contact Information
Genmab maintains a broad international presence across North America, Europe, and Asia Pacific, continuously striving to enhance patient outcomes through innovative therapies. For further inquiries or detailed information, interested parties can reach out to the following contacts:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
What is the reason for Genmab's capital increase?
The capital increase stems from the exercise of employee warrants, which helps align employee incentives with the company's growth.
How many new shares has Genmab issued?
Genmab has issued a total of 4,563 new shares as part of this capital increase.
What is the total share capital of Genmab after the increase?
After the increase, Genmab's total share capital is DKK 64,158,817.
Where will the new shares be listed?
The new shares will be listed on Nasdaq Copenhagen following the registration with the Danish Business Authority.
What is Genmab's goal regarding patient care?
Genmab aims to improve the lives of patients with innovative antibody medicines by 2030, showcasing its commitment to advancing healthcare.
